By: Benzinga
April 08, 2013 at 13:04 PM EDT
Celldex Presents Data on CDX-1127, Says Elicits Potent Activation of Cells, Says Complement to Ongoing Clinical Development
Celldex Therapeutics, Inc. (Nasdaq: CLDX ) today reported the results of an in vitro study analyzing the activation of human T cells with CDX-1127. CDX-1127 is a monoclonal antibody that binds CD27 and is designed to activate patients' immune cells against their cancer. The study further explored aspects related to both the potency and
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here